|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
|
Breast Carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Breast Carcinoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Breast Carcinoma
|
0.700 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model.
|
11230179 |
2001 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutation positive BRRS are at increased risk of at least breast cancer, possibly that of the thyroid as well.
|
14518069 |
2003 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN frequently shows loss of heterozygosity in breast and prostate cancers, and mutations in this gene are responsible for Cowden disease, a rare Mendelian syndrome that includes breast cancer as part of its phenotype.
|
16702386 |
2006 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN is an ubiquitously expressed tumor suppressor which plays a prominent role in the pathogenesis of many types of sporadic solid tumors, including breast cancer, as well as hematologic malignancies.
|
17405772 |
2007 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN expression has been shown to be correlated with NDRG1 in both prostate and breast cancer.
|
18653908 |
2008 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer.
|
20813970 |
2010 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway.
|
22710837 |
2012 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN loss associated with increased AKT phosphorylation, which was highest in ILC among all breast cancer subtypes.
|
26451490 |
2015 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN, a tumor suppressor gene, was confirmed as a target of miR-221/222 in breast cancer cell line MCF-7.
|
27044817 |
2016 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) insufficiency is commonly found in breast cancer patients with metastasis.
|
27466505 |
2016 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN is an important tumor suppressor in breast cancer.
|
28213783 |
2017 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN is a potential drug target for the development of individualized treatment in BC patients.
|
28885360 |
2017 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN deletion increased PI(3,4)P<sub>2</sub> levels in a mouse model of prostate cancer, and it inversely correlated with PI(3,4)P<sub>2</sub> levels across several EGF-stimulated prostate and breast cancer lines.
|
29056325 |
2017 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN and MFN2 protein expressions were negative correlated with Vmax and positively correlated with RI in breast cancer patients.
|
31535669 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer.
|
31594766 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A large-scale RNA interference screen to discover genes involved in trastuzumab resistance in breast cancer identified only PTEN as a modulator of drug sensitivity.
|
17936563 |
2007 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A new tumor suppressor gene PTEN/MMAC1 was recently isolated at chromosome 10q23 and found to be inactivated by point mutation or homozygous deletion in glioma, prostate and breast cancer.
|
9671402 |
1998 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A small group of cases are secondary to mutations in other breast cancer susceptibility genes, such as p53, PTEN or CDH1.
|
18544963 |
2008 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A total of 360 paired breast carcinoma and adjacent normal tissue samples from 180 sporadic breast cancer patients were included in the present study and examined for PTEN promoter methylation status by methylation-specific polymerase chain reaction.
|
26754093 |
2016 |
|
Breast Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
A total of 44 samples of invasive human breast cancer, 5 breast cancer cell lines and 16 samples of normal human breast tissue from young and elderly women were studied for methylation of the PTEN promoter by methylation-specific PCR and PTEN protein expression by immunohistochemistry.
|
15382065 |
2004 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation.
|
24356815 |
2014 |